Compare DVA & FMS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | DVA | FMS |
|---|---|---|
| Founded | 1994 | 1996 |
| Country | United States | Germany |
| Employees | N/A | 108165 |
| Industry | Misc Health and Biotechnology Services | Misc Health and Biotechnology Services |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 15.1B | 12.5B |
| IPO Year | 2003 | N/A |
| Metric | DVA | FMS |
|---|---|---|
| Price | $233.49 | $24.21 |
| Analyst Decision | Hold | Sell |
| Analyst Count | 4 | 2 |
| Target Price | ★ $156.75 | $30.00 |
| AVG Volume (30 Days) | ★ 701.6K | 597.4K |
| Earning Date | 05-05-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 2.57% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $13,643,069,000.00 | N/A |
| Revenue This Year | $3.85 | N/A |
| Revenue Next Year | $3.07 | $3.83 |
| P/E Ratio | $82.14 | ★ $15.62 |
| Revenue Growth | ★ 6.46 | N/A |
| 52 Week Low | $101.00 | $20.02 |
| 52 Week High | $238.64 | $27.64 |
| Indicator | DVA | FMS |
|---|---|---|
| Relative Strength Index (RSI) | 78.56 | 65.04 |
| Support Level | $145.58 | $22.50 |
| Resistance Level | N/A | $24.71 |
| Average True Range (ATR) | 6.03 | 0.35 |
| MACD | 1.61 | 0.04 |
| Stochastic Oscillator | 78.96 | 90.39 |
DaVita is one of the largest providers of dialysis services in the United States, boasting a market share of about 35%. The firm operates over 3,200 facilities worldwide, mostly in the US, and treats about 300,000 patients annually. Government payers dominate US dialysis reimbursement. DaVita receives about two-thirds of US sales at government (primarily Medicare) reimbursement rates, with the remainder coming from commercial insurers. While commercial insurers represent only about 10% of US patients treated, they represent nearly all of the profits generated by DaVita in the US dialysis business.
Fresenius Medical Care is the largest dialysis company in the world, treating nearly 300,000 patients from about 3,600 clinics worldwide as of December 2025. In addition to providing dialysis services, the firm is a leading supplier of dialysis products, including machines, dialyzers, and concentrates. Fresenius accounts for about 35% of the global dialysis products market, creating the world's only fully integrated dialysis business. Services account for about three-fourths of sales, while the balance is generated from medical technology products that enable dialysis treatments.